Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-031688
Filing Date
2024-08-13
Accepted
2024-08-13 17:10:41
Documents
79
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1969999
2 ex31-1.htm EX-31.1 16898
3 ex31-2.htm EX-31.2 17083
4 ex32-1.htm EX-32.1 7626
5 ex32-2.htm EX-32.2 7569
  Complete submission text file 0001493152-24-031688.txt   11081016

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cldi-20240630.xsd EX-101.SCH 75220
7 XBRL CALCULATION FILE cldi-20240630_cal.xml EX-101.CAL 74701
8 XBRL DEFINITION FILE cldi-20240630_def.xml EX-101.DEF 455538
9 XBRL LABEL FILE cldi-20240630_lab.xml EX-101.LAB 603865
10 XBRL PRESENTATION FILE cldi-20240630_pre.xml EX-101.PRE 506838
82 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1881044
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40789 | Film No.: 241202887
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)